{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:36Z","timestamp":1786984296380,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.amjcard.2016.02.032","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T03:16:51Z","timestamp":1456888611000},"page":"1575-1581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of Serum Fibrinogen, Total Stent Length, and Type of Acute Coronary Syndrome on 6-Month Major Adverse Cardiovascular Events and Bleeding After Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"117","author":[{"given":"Ehtisham","family":"Mahmud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattheus","family":"Ramsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Behnamfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Enright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushboo","family":"Kaushal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samhita","family":"Palakodeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phildrich","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2016.02.032_bib1","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.thromres.2010.01.003","article-title":"Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients","volume":"125","author":"Althoff","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.amjcard.2016.02.032_bib2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0300-8932(02)76670-0","article-title":"Prognostic value of fibrinogen in patients admitted with suspected unstable angina and non-q-wave myocardial infarction","volume":"55","author":"Arnau Vives","year":"2002","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.amjcard.2016.02.032_bib3","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1161\/01.CIR.96.12.4204","article-title":"Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Fragmin during Instability in Coronary Artery Disease","volume":"96","author":"Toss","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2016.02.032_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1053\/euhj.1998.1312","article-title":"Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function","volume":"20","author":"Verheggen","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.02.032_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0002-9149(96)90386-0","article-title":"Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q- wave myocardial infarction (TIMI IIIB Trial)","volume":"78","author":"Becker","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2016.02.032_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJM199503093321003","article-title":"Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris","volume":"332","author":"Thompson","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.02.032_bib7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.1987.03400090067035","article-title":"Fibrinogen and risk of cardiovascular disease. The Framingham Study","volume":"258","author":"Kannel","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2016.02.032_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(86)90111-X","article-title":"Haemostatic function and ischemic heart disease: principal results of the Northwick Park Study","volume":"2","author":"Meade","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2016.02.032_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/hrt.69.4.338","article-title":"Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study","volume":"69","author":"Lee","year":"1993","journal-title":"Br Heart J"},{"key":"10.1016\/j.amjcard.2016.02.032_bib10","first-page":"1799","article-title":"Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis","volume":"294","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2016.02.032_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jacc.2012.09.037","article-title":"Elevated plasma fibrinogen rather than residual platelet reactivity with clopidogrel is associated with an increased ischemic risk during elective percutaneous coronary intervention","volume":"61","author":"Ang","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.02.032_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in myocardial infarction (TIMI) trial\u2014Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.02.032_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1213\/ANE.0b013e31822e1853","article-title":"Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding","volume":"114","author":"Levy","year":"2012","journal-title":"Anesth Analg"},{"key":"10.1016\/j.amjcard.2016.02.032_bib14","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/trf.12431","article-title":"Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy","volume":"54","author":"Levy","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.amjcard.2016.02.032_bib15","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/CIRCULATIONAHA.108.833236","volume":"119","author":"Valgimigli","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2016.02.032_bib16","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jacc.2007.09.011","article-title":"Universal definition of myocardial infarction","volume":"50","author":"Thygesen","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.02.032_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/1753944708094736","article-title":"Monitoring oral antiplatelet therapy: is it justified?","volume":"2","author":"Ang","year":"2008","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.amjcard.2016.02.032_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/ehjci\/jet139","article-title":"Coronary artery calcification is inversely related to body morphology in patients with significant coronary artery disease: a three-dimensional intravascular ultrasound study","volume":"15","author":"Dangas","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2016.02.032_bib19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jcin.2011.07.005","article-title":"Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents","volume":"4","author":"Claessen","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.02.032_bib20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.amjcard.2003.07.025","article-title":"Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries","volume":"10","author":"Iakovou","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2016.02.032_bib21","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2016.02.032_bib22","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.02.032_bib23","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2016.02.032_bib24","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0140-6736(14)62052-3","article-title":"Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis","volume":"385","author":"Elmariah","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2016.02.032_bib25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2014.12.046","article-title":"Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.02.032_bib26","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2016.02.032_bib27","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916302922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916302922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T20:47:08Z","timestamp":1655844428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914916302922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0002914916302922"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.02.032","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Serum Fibrinogen, Total Stent Length, and Type of Acute Coronary Syndrome on 6-Month Major Adverse Cardiovascular Events and Bleeding After Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}